Pioneering Breakthroughs for SCN2A Mutations
RogCon — The SCN2A Company — is leading the discovery and development of novel treatments for SCN2A mutations that cause epilepsy, autism and other neurological disorders.
Join the International SCN2A Natural History Study
The SCN2A Natural History Study is a central element to facilitating new drug development for SCN2A patients. An NHS such as this one – being conducted by the top epileptologists and neurologists around the world – is a critical part of designing and implementing clinical trials and provides important regulatory information to help increase the FDA’s overall understanding of the condition and the impact of the novel treatments.
Learn More About Clinical Trials
RogCon is advancing several investigational new drugs for those affected by SCN2A mutations. We will call RogCon a success only when every child with an SCN2A mutation has access to a disease-modifying treatment. Clinical trials for our lead program are projected to begin shortly. Learn more about our clinical trials and how to participate.
RogCon was founded by two parents of children affected by SCN2A mutations, Alex Nemiroff and Kelley Dalby, and Dr. Steven Petrou, a renowned neuroscientist specializing in genetic epilepsy. Our founders came together to address the severe, unmet medical need of children and their families who are suffering from mutations in SCN2A, where no solutions currently exist. At RogCon, we are walking a path of relentless pursuit, taking deliberate action on a daily basis to bring novel, disease-modifying treatments to all patients.
The Latest on What’s Happening at RogCon
Partners on our Path to Discovery
Our path is enhanced through strong strategic collaborations and partnerships. Due to our expertise with SCN2A and our commitment to discover new therapies for SCN2A disease, RogCon has forged partnerships with Ionis Pharmaceuticals and The Florey Institute of Neuroscience, and has formed research collaborations with the foremost academic experts in genetics and epilepsy from around the world to support a number of ongoing programs.
In 2016, Ionis Pharmaceuticals (“Ionis”) [NASDAQ: IONS] and RogCon began a collaboration with the goal of developing new disease-modifying antisense oligonucleotide drugs to treat SCN2A disorders.
Our co-founder, Dr. Steven Petrou, leads The Florey Institute of Neuroscience and Mental Health, one of the largest and most highly respected brain research centers in the world.
RogCon U.R., a sister company of RogCon Biosciences, is focused on the research and development of novel, disease-modifying compounds that up-regulate SCN2A for the treatment of loss-of-function mutations in SCN2A causing autism and epilepsy. RogCon U.R. is working in partnership with the Florey Institute, among others, on this platform.